

Cover Story
Free
Congressional Panel Chair Questions Whether J&J, Brigham Reported Morcellation Adverse Events to FDA
By Matthew Bin Han Ong
The House Committee on Energy & Commerce has stepped into a key role in the controversy over power morcellation.
In Brief


Drugs & Targets
Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - NCI releases names of members of ad hoc working group—filling the void left by BSA
- Bhattacharya: New grant review criterion is “not political”
- ACOG says it will no longer accept federal funding
- Congress seems to have NCI’s back—is cautious optimism warranted? Two former directors say yes.